PER 2.41% 8.1¢ percheron therapeutics limited

our cornerstone investor, page-4

  1. 35,698 Posts.
    lightbulb Created with Sketch. 552
    If your cannon was based on the fact that Excaliard's aquisition was largely based on its lead product an Anitsense based product via ISIS (whom ANP also have agreement with) don't forget they ISIS have in excess of 24 Antisense lines with ANP only having world-wide rights to 3 of these of which all know based on current research & Excaliards clearly doesn't fit the mould. FWIW it would of been previously released as the move was a few days ago if there was any link.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.